These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2936571)
1. In vitro evaluation of heparin fractions: old vs. new methods. Walenga JM; Fareed J; Hoppensteadt D; Emanuele RM Crit Rev Clin Lab Sci; 1986; 22(4):361-89. PubMed ID: 2936571 [TBL] [Abstract][Full Text] [Related]
2. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions. Fareed J; Kumar A; Rock A; Walenga JM; Davis P Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364 [TBL] [Abstract][Full Text] [Related]
3. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169). Walenga JM; Fareed J; Hoppensteadt DA Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497 [TBL] [Abstract][Full Text] [Related]
4. Validity of serine protease inhibition tests in the evaluation and monitoring of the effect of heparin and its fractions. Hoppensteadt DA; Walenga JM; Fareed J Semin Thromb Hemost; 1985 Apr; 11(2):112-20. PubMed ID: 3898369 [TBL] [Abstract][Full Text] [Related]
5. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500 [TBL] [Abstract][Full Text] [Related]
6. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions. Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363 [TBL] [Abstract][Full Text] [Related]
7. Influence of different anticoagulant agents on fibrinopeptide a generation. Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437 [TBL] [Abstract][Full Text] [Related]
8. Laboratory assays for the evaluation of recombinant hirudin. Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197 [TBL] [Abstract][Full Text] [Related]
9. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate. Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496 [TBL] [Abstract][Full Text] [Related]
10. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291 [TBL] [Abstract][Full Text] [Related]
11. Monitoring the new antithrombotic drugs. Walenga JM; Hoppensteadt DA Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675 [TBL] [Abstract][Full Text] [Related]
12. A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske WP; Hoppensteadt D; Gray A; Walenga JM; Cunanan J; Myers L; Fareed J; Bayol A; Rigal H; Viskov C Thromb Res; 2011 Oct; 128(4):361-7. PubMed ID: 21458847 [TBL] [Abstract][Full Text] [Related]
13. Rationale behind the development of low molecular weight heparin derivatives. Hirsh J; Ofosu F; Buchanan M Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436 [TBL] [Abstract][Full Text] [Related]
14. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects. Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650 [TBL] [Abstract][Full Text] [Related]
15. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450 [TBL] [Abstract][Full Text] [Related]
16. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Racanelli A; Fareed J; Walenga JM; Coyne E Semin Thromb Hemost; 1985 Apr; 11(2):176-89. PubMed ID: 4035365 [No Abstract] [Full Text] [Related]
17. Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity. ten Cate H; Lamping RJ; Henny CP; Prins A; ten Cate JW Clin Chem; 1984 Jun; 30(6):860-4. PubMed ID: 6723041 [TBL] [Abstract][Full Text] [Related]
18. Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Norrheim L; Abildgaard U; Larsen ML; Lindahl AK Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967 [TBL] [Abstract][Full Text] [Related]
19. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213 [TBL] [Abstract][Full Text] [Related]
20. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf. Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]